Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous tocilizumab with or without DMARDs in rheumatoid arthritis patients with inadequate response to non-biologic DMARDs
2013-000342-19Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoints: Primary safety endpoints and Primary efficacy endpoints. Started Oct 2013; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2013-000342-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000342-19.